325 related articles for article (PubMed ID: 27265506)
1. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.
Yoo JH; Shi DS; Grossmann AH; Sorensen LK; Tong Z; Mleynek TM; Rogers A; Zhu W; Richards JR; Winter JM; Zhu J; Dunn C; Bajji A; Shenderovich M; Mueller AL; Woodman SE; Harbour JW; Thomas KR; Odelberg SJ; Ostanin K; Li DY
Cancer Cell; 2016 Jun; 29(6):889-904. PubMed ID: 27265506
[TBL] [Abstract][Full Text] [Related]
2. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice.
Huang JL; Urtatiz O; Van Raamsdonk CD
Cancer Res; 2015 Aug; 75(16):3384-97. PubMed ID: 26113083
[TBL] [Abstract][Full Text] [Related]
5. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
[TBL] [Abstract][Full Text] [Related]
6. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
[TBL] [Abstract][Full Text] [Related]
7. Effects of Oncogenic Gα
Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
[TBL] [Abstract][Full Text] [Related]
8. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
[TBL] [Abstract][Full Text] [Related]
9. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
11. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
12. Direct targeting of Gα
Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
[TBL] [Abstract][Full Text] [Related]
13. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
14. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
15. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
16. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma.
Ge Y; Shi S; Deng JJ; Chen XP; Song Z; Liu L; Lou L; Zhang X; Xiong XF
J Med Chem; 2021 Mar; 64(6):3131-3152. PubMed ID: 33715360
[TBL] [Abstract][Full Text] [Related]
18. Trametinib Induces the Stabilization of a Dual
Krebs FS; Gérard C; Wicky A; Aedo-Lopez V; Missiaglia E; Bisig B; Trimech M; Michielin O; Homicsko K; Zoete V
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126538
[TBL] [Abstract][Full Text] [Related]
19. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma.
Fan G; Liu L; Ye J; Xiao W; Xiong XF
Bioorg Chem; 2024 Feb; 143():107005. PubMed ID: 38043397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]